Clinical Trials Logo

Filter by:
NCT ID: NCT00430677 Terminated - Clinical trials for Systemic Lupus Erythematosus

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Start date: June 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.

NCT ID: NCT00425919 Terminated - Diabetes Mellitus Clinical Trials

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

NCT ID: NCT00412776 Terminated - Clinical trials for Head and Neck Cancer

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.

NCT ID: NCT00412620 Terminated - Schizophrenia Clinical Trials

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.

NCT ID: NCT00396955 Terminated - Osteoarthritis Clinical Trials

A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee

Start date: November 2006
Phase: Phase 2
Study type: Interventional

Objectives: Primary:To assess the efficacy and safety of PLA-695 in subjects with active osteoarthritis (OA) of the knee. Secondary:To determine the pharmacokinetics (PK) and pharmacodynamics (PD) of PLA-695 among dose levels. To assess health outcome measures. To assess the effect of PLA-695 on biomarkers related to clinical responses. To assess PLA-695 exposure-response relationship on PD, efficacy, and safety measures. To assess pharmacogenomics (PGX) analysis in OA.

NCT ID: NCT00396448 Terminated - Obesity Clinical Trials

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

NCT ID: NCT00396214 Terminated - Schizophrenia Clinical Trials

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Start date: April 2007
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.

NCT ID: NCT00391196 Terminated - Obesity Clinical Trials

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.

NCT ID: NCT00391066 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

LUCID
Start date: November 2006
Phase: Phase 2
Study type: Interventional

This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.

NCT ID: NCT00389675 Terminated - Hypertension Clinical Trials

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Darusentan
Start date: May 2007
Phase: Phase 3
Study type: Interventional

This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.